<DOC>
	<DOC>NCT01944527</DOC>
	<brief_summary>The purpose of this study is to evaluate the efficacy, safety and tolerability of direct-acting antivirals therapy in liver transplanted patients who experienced HCV recurrence. This cohort is multicentric with constitution of biobank (plasma, serum) and the prospective collect of biological and clinical data's in the liver transplanted patients with recurrent HCV infection and treated with direct-acting anti-HCV agents.</brief_summary>
	<brief_title>Use of Direct-acting Antiviral to Treat HCV Recurrence After Liver Transplantation (ANRSCO23CUPILT) Infection</brief_title>
	<detailed_description />
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Antiviral Agents</mesh_term>
	<criteria>Age &gt; 18 yearsold Liver transplanted patient Hepatitis C virus infection before transplantation HCV recurrence with a detectable HCV RNA before enrollment in cohort Use of at least one directacting antiviral agents with or without association with peginterferon and with or without association with ribavirin Treated by directacting antiviral agents or has been yet completed the treatment but still on follow up Affiliated to Health Insurance Written Signed consent form Pregnant or breastfeeding female</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>